Related Experiment Video

Updated: Apr 24, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K

Focusing on the Advances and Challenges of HER2-Targeted Therapy: Cutting-Edge Breakthroughs in Neoadjuvant Treatment

Anqi Shang1,2, Yunjing Xiong3, Min Li1,2

  • 1Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen University, Guangzhou, China.

Technology in Cancer Research & Treatment
|April 22, 2026
PubMed

Insights

HER2-positive breast cancer treatment has advanced with targeted therapies like trastuzumab and TKIs. Neoadjuvant therapy improves outcomes, with ongoing research focusing on novel agents and personalized strategies for better efficacy and reduced toxicity.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • HER2-positive breast cancer, comprising 15-20% of cases, presents aggressive behavior and poor prognosis.
  • HER2-targeted therapies, including monoclonal antibodies, TKIs, and ADCs, have revolutionized treatment outcomes for this subtype.

Purpose of the Study:

  • To review recent advancements in HER2-targeted neoadjuvant therapies for breast cancer.
  • To analyze the mechanisms, clinical efficacy, and synergistic effects of these therapies with chemotherapy.

Main Methods:

  • Comprehensive literature review of HER2-targeted neoadjuvant therapies.
  • Analysis of clinical trial data and mechanistic studies.

Main Results:

  • Neoadjuvant HER2-targeted therapy significantly improves pathological complete response (pCR) and survival rates.
  • Combination therapies show synergistic effects, enhancing treatment efficacy.
  • Novel agents like trastuzumab deruxtecan (T-DXd) demonstrate promising potential.

Conclusions:

  • HER2-targeted neoadjuvant therapies are crucial for managing HER2-positive breast cancer.
  • Personalized strategies using biomarkers (TILs, HER2 subtypes) are essential for optimizing treatment.
  • Future research should focus on novel agents and regimens to improve efficacy and minimize toxicity.
Keywords:
HER2-positive breast cancerHER2-targeted therapiesantibody-drug conjugates (ADCs)monoclonal antibodiesneoadjuvant therapytrastuzumabtyrosine kinase inhibitors (TKIs)

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K